A study of CAR T cells for patients with certain T or NK cell cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether a new treatment, called CAR T cells that target CD94, can help people with specific types of T or NK cell lymphoma or leukemia that have not responded to other treatments or have come back. The goal is to see if it is safe and works against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of T or NK cell cancer that has come back or not improved after at least one round of standard treatment.
- Your cancer cells have a protein called CD94 on at least half of them (this can be checked from a previous biopsy or a new one).
- You are in fairly good health, with a good ability to do daily activities (ECOG score 0-1).
- Your blood counts and organ function (like kidneys and liver) are within safe ranges for this treatment.
- You have not had certain other treatments recently, and any side effects from earlier treatments have mostly resolved.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests an “autologous” CAR T-cell treatment (made from your own T cells) that targets a cancer marker called CD79b in certain relapsed or hard-to-treat B-cell lymphomas. It’s designed to find a safe dose and see whether the treatment can shrink tumors and help control the lymphoma after prior therapies.
This early-phase (Phase 1) study tests a lab-made immune cell treatment (CD4 CAR T) for people with CD4+ leukemia or lymphoma that has come back or did not respond to standard treatment. The goal is to check safety and see how well the treatment works.
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
This trial tests a new type of CAR-T therapy designed to target and kill CD20-positive cancer cells in people with blood cancers like B-cell lymphoma or lymphocytic leukemia. It is an early study to see if this approach is safe and works.
This trial tests an immune cell treatment (CAR-NK cells) targeting a protein called CD70 found on cancer cells. It's for people with T cell lymphoma or acute myeloid leukemia that has come back or not responded to other treatments.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.